Neoadjuvant Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Neoadjuvant Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer	ECOG Score of 0-1; Expected Survival Time >6 Months; Female, Age ≥ 18 Years Old; Histologically Confirmed Cervical Cancer, FIGO Stage IB3, IIA2, IIB, IIIC, and Assessed by the Researcher as Resectable Lesion; Locally Advanced Cervical Cancer; No Previous Systemic Treatment for the Current Disease, Including Surgery, Antitumor Radiochemotherapy/Immunotherapy; Subjects Should Take Contraceptive Measures; Sufficient Organ Function; The Result of the Urine or Serum Pregnancy Test for the Subject is Negative	Recruiting	Phase 2	2025-08-05		NCT07104149

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Henan Provincial People's Hospital	95
Second Affiliated Hospital of Zhengzhou University	4
The First Affiliated Hospital of Zhengzhou University	203

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
The First Affiliated Hospital of Zhengzhou University	Zhengzhou	China	56